Lapisteride

Overview of the drug Lapisteride

Lapisteride
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Lapisteride is a pharmaceutical compound that functions as a 5-alpha-reductase inhibitor. It is primarily used in the treatment of conditions related to androgens, such as benign prostatic hyperplasia (BPH) and androgenic alopecia.

Mechanism of Action

Lapisteride works by inhibiting the enzyme 5-alpha-reductase, which is responsible for the conversion of testosterone into dihydrotestosterone (DHT). DHT is a potent androgen that plays a significant role in the development and progression of BPH and androgenic alopecia. By reducing the levels of DHT, Lapisteride helps in alleviating the symptoms associated with these conditions.

Clinical Uses

Lapisteride is primarily indicated for the treatment of:

• Benign prostatic hyperplasia: It helps in reducing the size of the enlarged prostate, thereby improving urinary flow and reducing the risk of urinary retention.
• Androgenic alopecia: It is used to slow down hair loss and promote hair regrowth in individuals with male pattern baldness.

Side Effects

Common side effects of Lapisteride include:

• Decreased libido
• Erectile dysfunction
• Ejaculation disorders

These side effects are generally mild and tend to resolve with continued use of the medication.

Pharmacokinetics

Lapisteride is well absorbed after oral administration. It undergoes extensive hepatic metabolism and is primarily excreted in the urine. The half-life of Lapisteride allows for once-daily dosing, which enhances patient compliance.

Contraindications

Lapisteride is contraindicated in:

• Women who are or may become pregnant, due to the risk of fetal harm.
• Patients with known hypersensitivity to the drug or any of its components.

Related pages

• 5-alpha-reductase inhibitor
• Benign prostatic hyperplasia
• Androgenic alopecia
• Dihydrotestosterone